South Korean E-cigarette Association sues government for economic damages.

Oct.17.2022
South Korean E-cigarette Association sues government for economic damages.
South Korea's electronic cigarette association has sued the government for causing economic losses to small e-cigarette businesses with incorrect information.

The Korean e-cigarette association has filed a lawsuit against the government, accusing it of causing economic losses to small business owners involved in the e-cigarette industry by providing incorrect information.


The Korea E-cigarette Association (KECA) has accused the government's health agency, the Ministry of Health and Welfare (MOHW), of damaging the reputation of small e-cigarette businesses and causing financial problems by urging the public to stop using liquid e-cigarettes in a press release dated February 23, 2019. KECA claimed that the basis for MOHW's decision was a notice from the US Food and Drug Administration (FDA) prohibiting the sale of liquid e-cigarettes due to the use of tetrahydrocannabinol, a main culprit in the US outbreak of severe lung illness associated with vaping that claimed eight lives and resulted in a ban on vaping products by the FDA in 2019. The South Korean Health Ministry, however, confirmed only one suspected case of lung injury related to e-cigarettes at the time of the press release and said that even that case was suspected to be from a smoker. According to a study published in the Journal of Korean Medical Science in December 2021, there have been no cases of severe pneumonia or lung injuries among users of liquid e-cigarettes. Despite these findings, KECA criticized the Health Ministry for not withdrawing its strong recommendation to suspend the use of liquid e-cigarettes and accused them of neglecting their duty. KECA also took issue with a press release issued by the Korean Disease Control and Prevention Agency (KDCA) on July 21, titled "Liquid E-cigarettes Disperse More and Farther Fine Dust than Cigarettes," saying that the measurements of fine dust by the KDCA were unavoidably higher in areas of higher humidity due to the method used in measuring them. KECA further argued that the comparison of liquid e-cigarettes and tobacco in the same environment is an inappropriate research method that fails to consider the unique characteristics of liquid e-cigarettes. KECA maintained that the government has already acknowledged that e-cigarettes are safer than tobacco, citing a 2017 test by the Ministry of Food and Drug Safety (MFDS) that found harmful substances in liquid e-cigarettes to be much lower than those in tobacco. KECA also pointed out that no tar or carbon monoxide was detected in liquid e-cigarettes, and the levels of formaldehyde and acetaldehyde were 1/20th and 1/500th those in cigarettes, respectively. Despite the significant differences in harmful substance contents, KECA protested that the Health Ministry's anti-smoking campaign has created a false perception that liquid e-cigarettes are as harmful as tobacco, causing great economic and psychological harm to e-cigarette business owners. KECA's Vice President Kim Du-hwan stated that KECA would do its utmost to win a legal battle against the government by preparing all scientific evidence and logical arguments to address the unfair treatment of small e-cigarette business owners who are unable to voice their concerns. A spokesperson for the Health Ministry responded to the lawsuit by stating that the relevant authorities would thoroughly examine the details of the complaint and work with other agencies such as KDCA and MFDS to address the issues.


Statement:


This article is compiled from third-party information and is intended solely for industry communication and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is only for industry-related communication and research purposes.


Due to limitations in our translation abilities, this article may not accurately reflect the original text. Please refer to the original version for precise information.


2FIRSTS maintains complete alignment with the Chinese government in its positions and statements regarding domestic, Hong Kong, Macau, Taiwan, and foreign issues.


The ownership of the compiled information belongs to the original media and authors. If there are any copyright infringements, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's parliament is scheduled to hold a first reading of amendments to the Tobacco Tax Act on September 24. The government plans annual tax increases from 2027 through 2030 covering cigarettes, heated tobacco, vaping liquids and other categories. It expects the reform to generate €756 million in additional revenue in 2027, rising to €3.589 billion in additional annual revenue by 2030. Ahead of the parliamentary debate, the German Association of the Tobacco Industry and Novel Products, or BVTE, launched the "Tabaksteuer mit Augenmaß" campaign backed by BAT, JTI, Philip Morris, Reemtsma and wholesale and retail groups.
Sep.23
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
Pennsylvania Lists 163 Vape Products Eligible for Sale, Including Vuse and JUUL; Previously Pending Chinese Brands Such as OXBAR Remain Absent, While Unlisted Products Including Geek Bar Face Enforcement From October 19
Pennsylvania Lists 163 Vape Products Eligible for Sale, Including Vuse and JUUL; Previously Pending Chinese Brands Such as OXBAR Remain Absent, While Unlisted Products Including Geek Bar Face Enforcement From October 19
Pennsylvania begins enforcing its electronic nicotine delivery system (ENDS) directory restrictions on October 19, 2026. The October 18 directory contained 163 product records from seven manufacturers, including Vuse, JUUL, NJOY, Logic and Naked 100. Geek Bar, RAZ and Lost Mary were absent. BAT, Altria, Japan Tobacco and JUUL collectively accounted for 112 records, or 68.7%, while Imperial Brands' blu had no listings. The directory included 15 disposable vape records, 40 bottled e-liquids and 10 products labeled 0mg, but no open-system refillable devices. Twenty-two manufacturer certifications remained under review. Four Logic models corresponding to Smoore's pending records were listed under the brand owner, while LYCO, OXBAR and Boulder/Rock had no approved directory entries.
Regulations
Oct.19
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Vaping brand PIXL has introduced the PIXL 5K reusable prefilled pod device in the UK, featuring a 2ml prefilled pod and a 4ml refill container with a combined e-liquid capacity of 6ml. The device uses 20mg/ml nicotine salt e-liquid and is advertised to deliver up to approximately 5,000 puffs. Available through UK retailers by August 2026, the PIXL 5K sits alongside the existing 12ml PIXL 8000. The UK's Vaping Products Duty took effect on October 1 at £0.22 per millilitre, producing theoretical duty amounts of £1.32 and £2.64 for the two products' respective full refill sets.
product
Oct.10
Canada Recalls Nearly 25,000 GTMBAR Vapes Over Child-Resistant Packaging Violations; Brand Linked to Shenzhen GTM Bar, with LK Vape as Importer and Distributor
Canada Recalls Nearly 25,000 GTMBAR Vapes Over Child-Resistant Packaging Violations; Brand Linked to Shenzhen GTM Bar, with LK Vape as Importer and Distributor
Health Canada announced a recall of 24,950 China-made GTMBAR 45K disposable vaping devices on November 13, 2026, citing non-compliance with child-resistant packaging requirements. The devices were sold in Canada between December 2024 and October 2026 and feature a 20mL e-liquid system with a nicotine concentration of 20 mg/mL. No related incidents or injuries had been reported as of November 12. Quebec-based LK Vape is the Canadian importer and distributor, while Shenzhen GTM bar Electronic Technology Co., Ltd. holds the GTMBAR trademark registration in the United Kingdom.
Regulations
Nov.16
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
U.S. nicotine pouch startup Skoka Inc. has raised $21.5 million and committed $15 million to an FDA regulatory and scientific research program. Founder Dan Aziz previously built dietary supplement brand Premama, which was acquired by Dr. Reddy's Laboratories in 2023. Skoka is combining proprietary formulations, ingredient transparency and equity investment from professional athletes. The company submitted a bundled PMTA covering 55 products on October 1, 2026. Aziz said Skoka declined an opportunity to enter retail in 2025, prioritizing product research and regulatory submissions instead. It now targets a U.S. retail launch in 2027, subject to FDA requirements. Its products have not received marketing authorization.
Business
Nov.04